Immunodiagnostics market seen reaching $35.76 billion by 2030

The Business Research Company says the global immunodiagnostics market will grow from $24.32 billion in 2025 to $26.16 billion in 2026, then climb to $35.76 billion by 2030. Rising chronic disease rates, automated lab systems and point-of-care testing are key demand drivers.

Why it matters: - Immunodiagnostics helps doctors detect disease earlier and monitor chronic conditions through antigen-antibody testing. - The market’s growth signals rising demand for faster, more precise diagnostics as chronic and infectious diseases increase. - Better testing can improve treatment decisions, especially for conditions that require ongoing monitoring.

What happened: - The Business Research Company released its 2026 immunodiagnostics market report on August 11, 2026. - The report sizes the global immunodiagnostics market at $24.32 billion in 2025 and $26.16 billion in 2026. - The report projects the market will reach $35.76 billion by 2030. - The report covers major regions including Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - North America held the largest share of the global market in 2025. - Download a free sample of the report. - View the full market report.

The details: - The report puts the market’s 2025-to-2026 growth at a 7.5% compound annual growth rate. - The projected 2026-to-2030 growth rate is 8.1%. - Growth in the recent period is tied to rising infectious and chronic disease incidence, expansion of clinical laboratory networks, stronger demand for early diagnosis, broader use of antibody-based diagnostics and standardized immunoassay technologies. - The forecast period is supported by personalized diagnostics, investment in automated laboratory systems, expansion of point-of-care immunodiagnostics, wider use of AI in result interpretation and more preventive healthcare testing. - Anticipated trends include automated immunoassay analyzers, high-sensitivity tests, rapid immunodiagnostic kits, multiplex testing and better laboratory data management systems. - Immunodiagnostics uses antigen-antibody interactions to detect serum insulin and other biomarkers. - The testing approach helps identify antibodies and parasite antigens.

Between the lines: - Chronic disease prevalence is becoming a major commercial driver for diagnostic makers because long-term conditions need repeated testing. - The report highlights a shift from traditional lab workflows toward automation, speed and more integrated data tools. - The inclusion of TAM analysis, company scoring matrices, forecasting dashboards and hotspot graphics suggests buyers want more decision-ready market intelligence, not just sizing data.

What’s next: - The market is expected to keep benefiting from preventive care, point-of-care expansion and AI-assisted interpretation. - More demand should flow toward automated systems and multiplex platforms as labs seek faster throughput and broader test panels. - The report points to continued regional opportunity across North America, Europe, Asia-Pacific and other global markets.

The bottom line: - Immunodiagnostics is moving from a steady-growth niche to a larger diagnostics category shaped by chronic disease, automation and faster testing needs.